Cargando…
COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts
The novel pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible to cause coronavirus disease-2019 (COVID-19). It is a global pandemic disease and has reached a new dimension with a higher death ratio. On 2 June 2020, World Health Organization (WHO) data showed more tha...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293532/ http://dx.doi.org/10.1016/j.phclin.2020.06.003 |
_version_ | 1783546327064379392 |
---|---|
author | Khan, Z. Karataş, Y. Ceylan, A.F. Rahman, H. |
author_facet | Khan, Z. Karataş, Y. Ceylan, A.F. Rahman, H. |
author_sort | Khan, Z. |
collection | PubMed |
description | The novel pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible to cause coronavirus disease-2019 (COVID-19). It is a global pandemic disease and has reached a new dimension with a higher death ratio. On 2 June 2020, World Health Organization (WHO) data showed more than 6,194,500 confirmed and 376,300 deaths globally due to the COVID-19. There are currently no approved medications or vaccines which have been claimed to be effective in COVID-19 prevention or treatment. Drug repurposing of available drugs and research studies for the search of new therapeutic agents are underway in various countries to try different combinations to treat their patients. It is too early to be sure of them as safe treatments because some reports seem to suggest some alarming side effects. However, a lot of work needs to be done to achieve a successful treatment result and the full safety and efficacy of the trial drugs will take some time to be developed. In this narrative perspective review, we addressed evidence-based literature on various possible antiviral medications, plant-derived antivirals drugs, and other valuable treatment options for COVID-19 management. |
format | Online Article Text |
id | pubmed-7293532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72935322020-06-14 COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts Khan, Z. Karataş, Y. Ceylan, A.F. Rahman, H. Le Pharmacien Hospitalier & Clinicien Review The novel pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible to cause coronavirus disease-2019 (COVID-19). It is a global pandemic disease and has reached a new dimension with a higher death ratio. On 2 June 2020, World Health Organization (WHO) data showed more than 6,194,500 confirmed and 376,300 deaths globally due to the COVID-19. There are currently no approved medications or vaccines which have been claimed to be effective in COVID-19 prevention or treatment. Drug repurposing of available drugs and research studies for the search of new therapeutic agents are underway in various countries to try different combinations to treat their patients. It is too early to be sure of them as safe treatments because some reports seem to suggest some alarming side effects. However, a lot of work needs to be done to achieve a successful treatment result and the full safety and efficacy of the trial drugs will take some time to be developed. In this narrative perspective review, we addressed evidence-based literature on various possible antiviral medications, plant-derived antivirals drugs, and other valuable treatment options for COVID-19 management. Elsevier Masson SAS. 2021-03 2020-06-13 /pmc/articles/PMC7293532/ http://dx.doi.org/10.1016/j.phclin.2020.06.003 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Khan, Z. Karataş, Y. Ceylan, A.F. Rahman, H. COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts |
title | COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts |
title_full | COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts |
title_fullStr | COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts |
title_full_unstemmed | COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts |
title_short | COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts |
title_sort | covid-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293532/ http://dx.doi.org/10.1016/j.phclin.2020.06.003 |
work_keys_str_mv | AT khanz covid19andtherapeuticdrugsrepurposinginhandtheneedforcollaborativeefforts AT karatasy covid19andtherapeuticdrugsrepurposinginhandtheneedforcollaborativeefforts AT ceylanaf covid19andtherapeuticdrugsrepurposinginhandtheneedforcollaborativeefforts AT rahmanh covid19andtherapeuticdrugsrepurposinginhandtheneedforcollaborativeefforts |